Thyroid gland - Revision history

Michael: /* See also */

2018-03-20T03:43:12Z

Michael: /* Riedel thyroiditis */

2017-10-17T15:30:17Z

Riedel thyroiditis

← Older revision		Revision as of 15:30, 17 October 2017
Line 207:		Line 207:
	==Riedel thyroiditis==		==Riedel thyroiditis==
	*[[AKA]] ''invasive fibrous thyroiditis''.<ref name=pmid21568724>{{Cite journal \| last1 = Fatourechi \| first1 = MM. \| last2 = Hay \| first2 = ID. \| last3 = McIver \| first3 = B. \| last4 = Sebo \| first4 = TJ. \| last5 = Fatourechi \| first5 = V. \| title = Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. \| journal = Thyroid \| volume = 21 \| issue = 7 \| pages = 765-72 \| month = Jul \| year = 2011 \| doi = 10.1089/thy.2010.0453 \| PMID = 21568724 }}</ref>		*[[AKA]] ''invasive fibrous thyroiditis''.<ref name=pmid21568724>{{Cite journal \| last1 = Fatourechi \| first1 = MM. \| last2 = Hay \| first2 = ID. \| last3 = McIver \| first3 = B. \| last4 = Sebo \| first4 = TJ. \| last5 = Fatourechi \| first5 = V. \| title = Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. \| journal = Thyroid \| volume = 21 \| issue = 7 \| pages = 765-72 \| month = Jul \| year = 2011 \| doi = 10.1089/thy.2010.0453 \| PMID = 21568724 }}</ref>
	~~===General===~~		{{Main\|Riedel thyroiditis}}
	~~Clinical features:<ref name=pmid21568724/>~~
	*Extremely rare.
	*Women > men.
	*Usually smokers.
	*May be associated with ''[[retroperitoneal fibrosis]]''.
	*May be hypothyroid.
	*+/-Obstructive symptoms.

	~~===Microscopic===~~
	~~Features:~~
	*Fibrosis.
	*Specimen often fragmented as it was difficult to remove.

	~~DDx:~~
	*[[Anaplastic thyroid carcinoma\|~~Anaplastic carcinoma]], spindle cell variant.~~

	==Hashimoto thyroiditis==		==Hashimoto thyroiditis==

Michael: /* Hyalinizing trabecular tumour */ split-out

2017-07-02T17:00:00Z

Hyalinizing trabecular tumour: split-out

← Older revision		Revision as of 17:00, 2 July 2017
Line 275:		Line 275:
	*[[AKA]] ''hyalinizing trabecular adenoma''.		*[[AKA]] ''hyalinizing trabecular adenoma''.
	*Abbreviated ''HTT''.		*Abbreviated ''HTT''.
	~~===General===~~		{{Main\|Hyalinizing trabecular tumour}}
	*Considered by some (e.g. Silvia Asa) to be a variant of [[papillary thyroid carcinoma]].<ref name=pmid11117782>{{~~cite journal~~ \|~~author=Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL \|title=~~Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics \|journal=Am. J. Surg. Pathol. \|volume=24 \|issue=12 \|pages=1622–6 \|year=2000 \|month=December \|pmid=11117782 \|doi= \|url=}}</ref>
	*Behaviour similar to papillary thyroid carcinoma - indolent.

	~~===Microscopic===~~
	~~Features:~~
	*Trabecular arrangement of cells.
	**May have "curved" trabeculae.
	*Extracellular space has hyaline material - '''key feature'''.
	*Cytoplasm mimics hyaline material in the extracellular space.

	~~DDx:~~
	*[[Papillary thyroid carcinoma]] (if one believes this is a separate entity).
	*[[Medullary thyroid carcinoma]] - not trabecular, nuclei not [[PTC]]-like.
	*[[Paraganglioma]].<ref>URL: [http://path.upmc.edu/cases/case465/dx.html http://path.upmc.edu/cases/case465/dx.html]. Accessed on: 17 January 2011.</ref>

	~~====Images====~~
	~~<gallery>~~
	~~Image: Hyalinized trabecular tumour - low mag.jpg \| HHT - low mag. (WC)~~
	~~Image: Hyalinized trabecular tumour - intermed mag.jpg \| HHT - intermed. mag. (WC)~~
	~~Image: Hyalinized trabecular tumour - high mag.jpg \| HHT - high mag. (WC)~~
	~~Image: Thyroid gland - high mag.jpg \| Thyroid gland - high mag. (WC)~~

	~~Image: Hyalinized trabecular tumour - 2 - intermed mag.jpg \| HHT - intermed. mag. (WC)~~
	~~Image: Hyalinized trabecular tumour - 2 - high mag.jpg \| HHT - high mag. (WC)~~

	~~Image: Hyalinized trabecular tumour - 3 - intermed mag.jpg \| HHT - intermed. mag. (WC)~~
	~~Image: Hyalinized trabecular tumour - 3 - high mag.jpg \| HHT - high mag. (WC)~~
	~~Image: Hyalinized~~ trabecular tumour ~~- 3 - very high mag.jpg \| HHT - very high mag. (WC)~~
	~~</gallery>~~
	~~www:~~
	*[http://archive.biomedcentral.com/1742-6413/3/17/figure/F2?highres=y HTT (biomedcentral.com)].<ref name=pmid16867191>{{Cite journal \| last1 = Baloch \| first1 = ZW. \| last2 = Puttaswamy \| first2 = K. \| last3 = Brose \| first3 = M. \| last4 = LiVolsi \| first4 = VA. \| title = Lack of BRAF mutations in hyalinizing trabecular neoplasm. \| journal = Cytojournal \| volume = 3 \| issue = \| pages = 17 \| month = \| year = 2006 \| doi = 10.1186/1742-6413-3-17 \| PMID = 16867191 }}</ref>
	*[http://www.ispub.com/journal/the-internet-journal-of-endocrinology/volume-2-number-1/hyalinizing-trabecular-neoplasm-of-the-thyroid-controversies-in-management.article-g01.fs.jpg HTT (ispub.com)].<ref>URL: [http://www.ispub.com/journal/the-internet-journal-of-endocrinology/volume-2-number-1/hyalinizing-trabecular-neoplasm-of-the-thyroid-controversies-in-management.html http://www.ispub.com/journal/the-internet-journal-of-endocrinology/volume-2-number-1/hyalinizing-trabecular-neoplasm-of-the-thyroid-controversies-in-management.html]. Accessed on: 1 January 2012.</ref>

	~~===IHC===~~
	*Thyroglobulin +ve.
	*NSE +ve.
	*[[Ki-67 membranous pattern]].<ref name=pmid17525638>{{Cite journal \| last1 = Leonardo \| first1 = E. \| last2 = Volante \| first2 = M. \| last3 = Barbareschi \| first3 = M. \| last4 = Cavazza \| first4 = A. \| last5 = Dei Tos \| first5 = AP. \| last6 = Bussolati \| first6 = G. \| last7 = Papotti \| first7 = M. \| title = Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? \| journal = Appl Immunohistochem Mol Morphol \| volume = 15 \| issue = 2 \| pages = 220-3 \| month = Jun \| year = 2007 \| doi = 10.1097/01.pai.0000213122.66096.f0 \| PMID = 17525638 }}~~</ref>~~

	==Hürthle cell neoplasm==		==Hürthle cell neoplasm==

Michael: /* IHC */

2017-07-02T16:55:52Z

IHC

← Older revision		Revision as of 16:55, 2 July 2017
Line 312:		Line 312:
	*Thyroglobulin +ve.		*Thyroglobulin +ve.
	*NSE +ve.		*NSE +ve.
			*[[Ki-67 membranous pattern]].<ref name=pmid17525638>{{Cite journal \| last1 = Leonardo \| first1 = E. \| last2 = Volante \| first2 = M. \| last3 = Barbareschi \| first3 = M. \| last4 = Cavazza \| first4 = A. \| last5 = Dei Tos \| first5 = AP. \| last6 = Bussolati \| first6 = G. \| last7 = Papotti \| first7 = M. \| title = Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? \| journal = Appl Immunohistochem Mol Morphol \| volume = 15 \| issue = 2 \| pages = 220-3 \| month = Jun \| year = 2007 \| doi = 10.1097/01.pai.0000213122.66096.f0 \| PMID = 17525638 }}</ref>

	==Hürthle cell neoplasm==		==Hürthle cell neoplasm==

Michael: /* C-cell hyperplasia */ +adenolipoma of thyroid

2016-11-21T02:21:42Z

C-cell hyperplasia: +adenolipoma of thyroid

← Older revision		Revision as of 02:21, 21 November 2016
Line 230:		Line 230:
	*Abbreviated ''CCH''.		*Abbreviated ''CCH''.
	{{Main\|C-cell hyperplasia}}		{{Main\|C-cell hyperplasia}}

			==Adenolipoma of the thyroid==
			{{Main\|Adenolipoma of the thyroid}}

	=Malignant neoplasm=		=Malignant neoplasm=

Michael at 05:37, 2 January 2016

2016-01-02T05:37:06Z

← Older revision		Revision as of 05:37, 2 January 2016
Line 127:		Line 127:
	*p63 +ve.		*p63 +ve.
	**-ve in clear cells.		**-ve in clear cells.
	*CEA +ve (polyconal).<ref name=pmid7509563>{{cite journal \|author=Mizukami Y, Nonomura A, Michigishi T, ''et al.'' \|title=Solid cell nests of the thyroid. A histologic and immunohistochemical study \|journal=Am. J. Clin. Pathol. \|volume=101 \|issue=2 \|pages=186–91 \|year=1994 \|month=February \|pmid=7509563 \|doi= \|url=}}</ref>		*[[CEA]] +ve (polyconal).<ref name=pmid7509563>{{cite journal \|author=Mizukami Y, Nonomura A, Michigishi T, ''et al.'' \|title=Solid cell nests of the thyroid. A histologic and immunohistochemical study \|journal=Am. J. Clin. Pathol. \|volume=101 \|issue=2 \|pages=186–91 \|year=1994 \|month=February \|pmid=7509563 \|doi= \|url=}}</ref>
	**+ve also in clear cells.		**+ve also in clear cells.
	*Chromogranin A +ve ~45% of cases.<ref name=pmid7509563/>		*Chromogranin A +ve ~45% of cases.<ref name=pmid7509563/>

Michael: /* Hürthle cell neoplasm */ split out

2015-12-15T04:47:33Z

Hürthle cell neoplasm: split out

← Older revision		Revision as of 04:47, 15 December 2015
Line 313:		Line 313:
	*[[AKA]] ''oncocytic neoplasm''.		*[[AKA]] ''oncocytic neoplasm''.
	*Also spelled ''Hurthle cell neoplasm''.		*Also spelled ''Hurthle cell neoplasm''.
			{{Main\|Hürthle cell neoplasm}}
	~~===General===~~
	*Incidence: uncommon.
	*This is a general category - includes:
	**Hürthle cell adenoma.
	**Hürthle cell carcinoma.

	*Some advocate ''total thyroidectomy'' for all Hürthle cell neoplasms, as it is difficult to reliably differentiate adenomas and carcinomas.<ref name=pmid9697901>{{~~Cite journal~~ \| ~~last1 = Wasvary \| first1 = H. \| last2 = Czako \| first2 = P. \| last3 = Poulik \| first3 = J. \| last4 = Lucas \| first4 = R. \| title = Unilateral lobectomy for Hurthle~~ cell ~~adenoma. \| journal = Am Surg \| volume = 64 \| issue = 8 \| pages = 729-32; discussion 732-3 \| month = Aug \| year = 1998 \| doi = \| PMID = 9697901 }}</ref>~~
	*It can be understood as a special type of ''follicular neoplasm~~'' (including ''[[follicular thyroid adenoma]]'' and ''[[follicular thyroid carcinoma]]'').<ref name=Ref_EP104>{{Ref EP\|104}}</ref>~~
	*High stage HCC has a poor prognosis.<ref name=pmid25259908>{{Cite journal \| last1 = Chindris \| first1 = AM. \| last2 = Casler \| first2 = JD. \| last3 = Bernet \| first3 = VJ. \| last4 = Rivera \| first4 = M. \| last5 = Thomas \| first5 = C. \| last6 = Kachergus \| first6 = JM. \| last7 = Necela \| first7 = BM. \| last8 = Hay \| first8 = ID. \| last9 = Westphal \| first9 = SA. \| title = Clinical and molecular features of Hürthle cell carcinoma of the thyroid. \| journal = J Clin Endocrinol Metab \| volume = 100 \| issue = 1 \| pages = 55-62 \| month = Jan \| year = 2015 \| doi = 10.1210/jc.2014-1634 \| PMID = 25259908 }}</ref>

	~~====Adenoma vs. carcinoma====~~
	~~Suggestive for carcinoma:<ref name=pmid9697901/>~~
	*Male.
	*>4 cm
	**Adenomas usu. <3 cm.
	~~Definite for carcinoma:<ref name=pmid9697901/>~~
	*Lymphovascular invasion.
	*Capsular invasion.

	~~===Gross===~~
	*Yellow.
	*Encapsulated.

	~~===Microscopic===~~
	~~Features:<ref name=Ref_EP104>{{Ref EP\|104}}</ref>~~
	*Oncocytes >= 75% of cells:
	**Abundant granular, eosinophilic cytoplasm.
	**Round regular nucleus +/- prominent nucleolus.
	*+/-Degenerative changes.

	~~Negatives:~~
	*Lack nuclear features of [[papillary thyroid carcinoma]].
	*Lack features of [[medullary thyroid carcinoma]].

	DDx:<ref name=pmid18684023>{{cite journal \|author=Montone KT, Baloch ZW, LiVolsi VA \|title=The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review \|journal=Arch. Pathol. Lab. Med. \|volume=132 \|issue=8 \|pages=1241–50 \|year=2008 \|month=August \|pmid=18684023 \|doi= \|url=}}</ref>
	*Papillary thyroid carcinoma oncocytic variant.
	*Medullary thyroid carcinoma oncocytic variant.
	*Others.

	~~===IHC===~~
	~~Features:~~
	*TTF-1 +ve (2 of 6 cases in Bejarno ''et al.'',<ref name=pmid10981870>{{Cite journal \| last1 = Bejarano \| first1 = PA. \| last2 = Nikiforov \| first2 = YE. \| last3 = Swenson \| first3 = ES. \| last4 = Biddinger \| first4 = PW. \| title = Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. \| journal = Appl Immunohistochem Mol Morphol \| volume = 8 \| issue = 3 \| pages = 189-94 \| month = Sep \| year = 2000 \| doi = \| PMID = 10981870 }}</ref> or 6 of 6 cases in Choi ''et al.''<ref name=pmid16224162/>).
	*Thyroglobulin (6 of 6 cases<ref name=pmid10981870/>).
	*CK7 (4 of 6 cases<ref name=pmid10981870/>).
	*HBME-1 +ve (focal in 4 of 6 cases<ref name=pmid16224162>{{Cite journal \| last1 = Choi \| first1 = YL. \| last2 = Kim \| first2 = MK. \| last3 = Suh \| first3 = JW. \| last4 = Han \| first4 = J. \| last5 = Kim \| first5 = JH. \| last6 = Yang \| first6 = JH. \| last7 = Nam \| first7 = SJ. \| title = Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. \| journal = J Korean Med Sci \| volume = 20 \| issue = 5 \| pages = 853-9 \| month = Oct \| year = 2005 \| doi = \| PMID = 16224162 }}~~</ref>).~~
	*HCK -ve (6 of 6 cases<ref name=pmid16224162/>).
	*CK19 +ve (focal in 4 of 6 cases<ref name=pmid16224162/>).

	==Minocycline associated thyroid pigmentation==		==Minocycline associated thyroid pigmentation==

Michael: /* IHC */

2015-12-10T16:36:17Z

IHC

← Older revision		Revision as of 16:36, 10 December 2015
Line 360:		Line 360:
	*HBME-1 +ve (focal in 4 of 6 cases<ref name=pmid16224162>{{Cite journal \| last1 = Choi \| first1 = YL. \| last2 = Kim \| first2 = MK. \| last3 = Suh \| first3 = JW. \| last4 = Han \| first4 = J. \| last5 = Kim \| first5 = JH. \| last6 = Yang \| first6 = JH. \| last7 = Nam \| first7 = SJ. \| title = Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. \| journal = J Korean Med Sci \| volume = 20 \| issue = 5 \| pages = 853-9 \| month = Oct \| year = 2005 \| doi = \| PMID = 16224162 }}</ref>).		*HBME-1 +ve (focal in 4 of 6 cases<ref name=pmid16224162>{{Cite journal \| last1 = Choi \| first1 = YL. \| last2 = Kim \| first2 = MK. \| last3 = Suh \| first3 = JW. \| last4 = Han \| first4 = J. \| last5 = Kim \| first5 = JH. \| last6 = Yang \| first6 = JH. \| last7 = Nam \| first7 = SJ. \| title = Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. \| journal = J Korean Med Sci \| volume = 20 \| issue = 5 \| pages = 853-9 \| month = Oct \| year = 2005 \| doi = \| PMID = 16224162 }}</ref>).
	*HCK -ve (6 of 6 cases<ref name=pmid16224162/>).		*HCK -ve (6 of 6 cases<ref name=pmid16224162/>).
			*CK19 +ve (focal in 4 of 6 cases<ref name=pmid16224162/>).

	==Minocycline associated thyroid pigmentation==		==Minocycline associated thyroid pigmentation==

Michael: /* IHC */

2015-12-10T16:35:12Z

IHC

← Older revision		Revision as of 16:35, 10 December 2015
Line 355:		Line 355:
	===IHC===		===IHC===
	Features:		Features:
	*TTF-1 (2 of 6 cases<ref name=pmid10981870>{{Cite journal \| last1 = Bejarano \| first1 = PA. \| last2 = Nikiforov \| first2 = YE. \| last3 = Swenson \| first3 = ES. \| last4 = Biddinger \| first4 = PW. \| title = Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. \| journal = Appl Immunohistochem Mol Morphol \| volume = 8 \| issue = 3 \| pages = 189-94 \| month = Sep \| year = 2000 \| doi = \| PMID = 10981870 }}</ref>).		*TTF-1 +ve (2 of 6 cases in Bejarno ''et al.'',<ref name=pmid10981870>{{Cite journal \| last1 = Bejarano \| first1 = PA. \| last2 = Nikiforov \| first2 = YE. \| last3 = Swenson \| first3 = ES. \| last4 = Biddinger \| first4 = PW. \| title = Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. \| journal = Appl Immunohistochem Mol Morphol \| volume = 8 \| issue = 3 \| pages = 189-94 \| month = Sep \| year = 2000 \| doi = \| PMID = 10981870 }}</ref> or 6 of 6 cases in Choi ''et al.''<ref name=pmid16224162/>).
	*Thyroglobulin (6 of 6 cases<ref name=pmid10981870/>).		*Thyroglobulin (6 of 6 cases<ref name=pmid10981870/>).
	*CK7 (4 of 6 cases<ref name=pmid10981870/>).		*CK7 (4 of 6 cases<ref name=pmid10981870/>).
			*HBME-1 +ve (focal in 4 of 6 cases<ref name=pmid16224162>{{Cite journal \| last1 = Choi \| first1 = YL. \| last2 = Kim \| first2 = MK. \| last3 = Suh \| first3 = JW. \| last4 = Han \| first4 = J. \| last5 = Kim \| first5 = JH. \| last6 = Yang \| first6 = JH. \| last7 = Nam \| first7 = SJ. \| title = Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. \| journal = J Korean Med Sci \| volume = 20 \| issue = 5 \| pages = 853-9 \| month = Oct \| year = 2005 \| doi = \| PMID = 16224162 }}</ref>).
			*HCK -ve (6 of 6 cases<ref name=pmid16224162/>).

	==Minocycline associated thyroid pigmentation==		==Minocycline associated thyroid pigmentation==

Michael: /* Hürthle cell neoplasm */

2015-12-10T15:59:36Z

Hürthle cell neoplasm

← Older revision		Revision as of 15:59, 10 December 2015
Line 322:		Line 322:
	*Some advocate ''total thyroidectomy'' for all Hürthle cell neoplasms, as it is difficult to reliably differentiate adenomas and carcinomas.<ref name=pmid9697901>{{Cite journal \| last1 = Wasvary \| first1 = H. \| last2 = Czako \| first2 = P. \| last3 = Poulik \| first3 = J. \| last4 = Lucas \| first4 = R. \| title = Unilateral lobectomy for Hurthle cell adenoma. \| journal = Am Surg \| volume = 64 \| issue = 8 \| pages = 729-32; discussion 732-3 \| month = Aug \| year = 1998 \| doi = \| PMID = 9697901 }}</ref>		*Some advocate ''total thyroidectomy'' for all Hürthle cell neoplasms, as it is difficult to reliably differentiate adenomas and carcinomas.<ref name=pmid9697901>{{Cite journal \| last1 = Wasvary \| first1 = H. \| last2 = Czako \| first2 = P. \| last3 = Poulik \| first3 = J. \| last4 = Lucas \| first4 = R. \| title = Unilateral lobectomy for Hurthle cell adenoma. \| journal = Am Surg \| volume = 64 \| issue = 8 \| pages = 729-32; discussion 732-3 \| month = Aug \| year = 1998 \| doi = \| PMID = 9697901 }}</ref>
	*It can be understood as a special type of ''follicular neoplasm'' (including ''[[follicular thyroid adenoma]]'' and ''[[follicular thyroid carcinoma]]'').<ref name=Ref_EP104>{{Ref EP\|104}}</ref>		*It can be understood as a special type of ''follicular neoplasm'' (including ''[[follicular thyroid adenoma]]'' and ''[[follicular thyroid carcinoma]]'').<ref name=Ref_EP104>{{Ref EP\|104}}</ref>
			*High stage HCC has a poor prognosis.<ref name=pmid25259908>{{Cite journal \| last1 = Chindris \| first1 = AM. \| last2 = Casler \| first2 = JD. \| last3 = Bernet \| first3 = VJ. \| last4 = Rivera \| first4 = M. \| last5 = Thomas \| first5 = C. \| last6 = Kachergus \| first6 = JM. \| last7 = Necela \| first7 = BM. \| last8 = Hay \| first8 = ID. \| last9 = Westphal \| first9 = SA. \| title = Clinical and molecular features of Hürthle cell carcinoma of the thyroid. \| journal = J Clin Endocrinol Metab \| volume = 100 \| issue = 1 \| pages = 55-62 \| month = Jan \| year = 2015 \| doi = 10.1210/jc.2014-1634 \| PMID = 25259908 }}</ref>

	====Adenoma vs. carcinoma====		====Adenoma vs. carcinoma====

← Older revision		Revision as of 03:43, 20 March 2018
Line 297:		Line 297:
	===Stains===		===Stains===
	*[[Fontana-Masson stain]] +ve.<ref name=pmid10615019>{{Cite journal \| last1 = Sant'Ambrogio \| first1 = S. \| last2 = Connelly \| first2 = J. \| last3 = DiMaio \| first3 = D. \| title = Minocycline pigmentation of heart valves. \| journal = Cardiovasc Pathol \| volume = 8 \| issue = 6 \| pages = 329-32 \| month = \| year = \| doi = \| PMID = 10615019 }}</ref>		*[[Fontana-Masson stain]] +ve.<ref name=pmid10615019>{{Cite journal \| last1 = Sant'Ambrogio \| first1 = S. \| last2 = Connelly \| first2 = J. \| last3 = DiMaio \| first3 = D. \| title = Minocycline pigmentation of heart valves. \| journal = Cardiovasc Pathol \| volume = 8 \| issue = 6 \| pages = 329-32 \| month = \| year = \| doi = \| PMID = 10615019 }}</ref>

			==Sclerosing mucoepidermoid carcinoma with eosinophilia==
			{{Main\|Sclerosing mucoepidermoid carcinoma with eosinophilia}}

	=See also=		=See also=